Egyptian hospitals uncover the hidden toll of a rare kidney disease
NCT ID NCT07218536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews medical records of 200 people diagnosed with a rare blood and kidney disease called aHUS in Egyptian hospitals. Researchers want to learn about patient symptoms, treatments, and long-term health to help doctors diagnose and manage the disease better. No new treatments are tested; the goal is to gather information to improve future care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
NOT_YET_RECRUITINGAl Mansurah, Egypt
-
Research Site
RECRUITINGAlexandria, Egypt
-
Research Site
RECRUITINGAsyut, Egypt
-
Research Site
RECRUITINGCairo, Egypt
-
Research Site
NOT_YET_RECRUITINGNew Cairo, Egypt
-
Research Site
RECRUITINGNew Cairo, Egypt
-
Research Site
RECRUITINGTanta, Egypt
-
Research Site
RECRUITINGZagazig, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for aHUS patients: Long-Term iptacopan study launches
- Skin biopsies could unlock hidden genetic diagnoses
- Real-World study tracks Ravulizumab's impact on rare kidney disease
- New pill shows promise for rare blood disorder aHUS
- New drug ravulizumab aims to control rare blood disorder aHUS
- Promising aHUS drug trial stalls after only 6 patients enrolled